NCT04807868

AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 1,250 (estimated)
• Sponsor: AdventHealth Translational Research Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to create a resource that will advance research that is focused on discovery of novel therapies, risk stratification, and aggressive interventions for those at highest risk for non-alcoholic fatty liver disease (NAFLD). To achieve this, we will generate a biobank of liver tissue collected during standard of care liver biopsies. Paired blood/urine samples, FibroScan and relevant data will also be collected.

Conditions

• Non-Alcoholic Fatty Liver Disease

Interventions

Type	Name	Description
PROCEDURE	Standard of care liver biopsy	Patients undergoing a standard of care liver biopsy for any reason who are willing to participate will be consented for collecting additional biopsy tissue for research purposes. 1-2 additional biopsy tissue cores will be collected for research. Liver tissue will be biobanked for future use.
OTHER	Fibroscan	A FibroScan will be performed to evaluate longitudinal changes in liver fat and fibrosis.
OTHER	Biospecimen Collection	Blood and urine will be collected.

Timeline

• Start date: 2021-04-22
• Primary completion: 2025-12-01
• Completion: 2026-03-01
• First posted: 2021-03-19
• Last updated: 2025-03-13

Locations

1 site across 1 country: United States